Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis. Reversal with VP-16 and indomethacin.
Clinicopathologic and histopathologic evidence of both endoperoxidation with hyperprostaglandinemia and hyperlipidemia in a 5-week-old infant with a hemophagocytic syndrome is reported. Institution of histiocytolytic (VP-16) and cyclo-oxygenase inhibitor (indomethacin) therapies returned the prostaglandin levels and lipid profile to a nearly normal state coincidental with clinical recovery. It appears that by reducing the cell mass of histiocytes and controlling the over-production of prostaglandins, some types of hemophagocytic syndrome can be reversed.
D015237:Dinoprost; D015232:Dinoprostone; D005047:Etoposide / Q000627:therapeutic use*; D005947:Glucose / Q000627:therapeutic use; D006644:Histiocytes / Q000473:pathology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D007213:Indomethacin / Q000627:therapeutic use*; D007223:Infant; D008054:Lipid Peroxides / Q000097:blood; D008099:Liver / Q000473:pathology; D008206:Lymphatic Diseases / Q000150:complications*; D008218:Lymphocytosis / Q000150:complications; D008297:Male; D010587:Phagocytosis; D011458:Prostaglandins E / Q000097:blood*; D011460:Prostaglandins F / Q000097:blood; D014810:Vitamin E / Q000627:therapeutic use
D008054:Lipid Peroxides; D011458:Prostaglandins E; D011460:Prostaglandins F; D014810:Vitamin E; D005047:Etoposide; D015237:Dinoprost; D005947:Glucose; D015232:Dinoprostone; D007213:Indomethacin